• Home
  • Store
    • Newsletter Subscriptions
    • Multimedia Subscriptions
    • Books
    • eBooks
    • ABPN SA Courses
  • CME Center
  • Multimedia
    • Podcast
    • Webinars
    • Blog
  • Newsletters
    • General Psychiatry
    • Child Psychiatry
    • Addiction Treatment
    • Hospital Psychiatry
    • Geriatric Psychiatry
  • Log In
  • Register
  • Welcome
  • Sign Out
  • Subscribe
Home » Nuplazid: Novel Mechanism, Modest Benefits

Nuplazid: Novel Mechanism, Modest Benefits

March 30, 2020
Randall Moore, MD, JD. and Chris Aiken, MD.
From The Carlat Psychiatry Report
Issue Links: Learning Objectives | Editorial Information | PDF of Issue
Randall Moore, MD, JD. Clinical Associate Professor, Department of Psychiatry and Behavioral Sciences at Texas A & M University Health Science Center College of Medicine. Chris Aiken, MD. Editor-in-Chief of TCPR. Practicing psychiatrist, Winston-Salem, NC. Dr. Moore and Dr. Aiken have disclosed that they have no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Psychosis can be a paralyzing dilemma for patients with Parkinson’s disease (PD). Most antipsychotics worsen the motor symptoms of PD, while the dopaminergic drugs that treat PD can worsen the psychosis. Psychosis afflicts up to 60% of patients with PD, and it is the leading cause of nursing home placement in these patients (Hacksell U et al, Neurochem Res 2014;39(10):2008–2017).


In 2016, the FDA approved pimavanserin (Nuplazid) for Parkinson’s-related psychosis. This medication does not worsen the motor symptoms of Parkinson’s. Pimavanserin is a highly selective 5-HT2A inverse agonist that binds minimally with dopaminergic, histaminergic, and muscarinic receptors. Research suggests that overactive 5-HT2A signaling contributes to psychosis in PD (Hawkins T et al, Neurol Clin Pract 2017;7:157–162). Clinical evidence for this concept comes from clozapine, which, in low doses, blocks 5-HT2A receptors with minimal dopamine blockade. A review found that low doses of clozapine have proven efficacious in treating Parkinson’s psychosis (Cook K et al, Mov Disord 2017;32(S2)).


Safety and efficacy
Pimavanserin’s benefits in Parkinson’s psychosis are real, but very modest. In a meta-analysis of four randomized controlled trials, pimavanserin led to a 2.3 point reduction in psychotic symptoms compared to placebo on a 100-point rating scale, the SAPS H+D, a modified version of the Scale for the Assessment of Positive Symptoms (Yasue I et al, J Alzheimers Dis 2016;50:733–740). This 2-point difference could be achieved by resolution of a mild delusion, an improvement that may not always be clinically significant.


There was also a concerning risk of bias in these studies. Problems included neglecting to report the primary outcome in one of the treatment arms, leaving out important details about the randomization and blinding, relying on an unvalidated rating scale, and excluding patients with cognitive impairment (Mini Mental Status Exam < 21) (Cummings J et al, Lancet 2014;383(9916):533–540).


Outside of pimavanserin, clozapine is the best-studied antipsychotic for Parkinson’s psychosis. In low doses (12.5–50 mg), clozapine outperformed placebo without worsening motor symptoms in two randomized controlled trials. However, clozapine’s numerous medical risks make it a difficult choice for this syndrome. Quetia­pine and ziprasidone also have low levels of extrapyramidal side effects, though the evidence for their efficacy in Parkinson’s psychosis is minimal or mixed (Cook K et al, Mov Disord 2017;32(S2)).


Like other antipsychotics, pimavanserin’s benefits build up over about 2 weeks. The recommended dose is 34 mg daily. Assess the patient’s psychotic symptoms carefully before and after prescribing it, and consider discontinuing it if there is no clear improvement. Monitor for side effects, which include nausea, imbalance, and peripheral edema. Although pimavanserin is indicated for delusions and hallucinations, it can also cause new hallucinations (the rate was 5% with pimavanserin vs 3% with placebo). Other psychiatric side effects include aggression and confusional states.


Antipsychotics may have only modest benefits in Parkinson’s psychosis, but other interventions that can help (Schubmehl S et al, Am J Geriatr Psychiatry 2018;26(10):1014) include:



  1. Reduce dopaminergic medications

  2. Teach caregivers how to redirect patients

  3. Keep the lights on during the day to minimize visual hallucinations

  4. Play soothing music and address any hearing loss or tinnitus to minimize auditory hallucinations


Expanding use
Since its approval for Parkinson’s psychosis, pimavanserin has been tested in a variety of other conditions, including schizophrenia, Alzheimer’s disease with psychosis, depression, and antidepressant-induced sexual dysfunction. The ­majority of the available studies for off-label uses constitute low-quality and often negative evidence.


In major depression, pimavanserin successfully augmented an SSRI or SNRI in patients who had failed to respond to the antidepressant (n­ = 207). Pimavanserin separated from placebo at 1 week in this 10-week study, with a medium effect size (0.5–0.6). It’s a promising result, but the study needs replication (Fava M et al, J Clin Psychiatry 2019;80(6)).


Costs and coverage
Without insurance, pimavanserin costs over $3,000 per month. Most Medicare plans and commercial insurers cover it, though prior authorizations are often required. CoverMyMeds.com can assist with prior authorizations, and the Nuplazid website has a handy program (www.nuplazid.com/nuplazidconnect) that quickly checks coverage. Commercial insurers benefit from a $0 copay card, but the copay can be prohibitive for patients who are on governmental insurance.


TCPR Verdict: Antipsychotics are not particularly effective in Parkinson’s psychosis. Pimavanserin has FDA approval for this condition, but its benefits are modest and the price is high. Low-dose clozapine, though not FDA approved, is also helpful. For many of these patients, the psychosis will persist despite antipsychotic therapy. Other options, including minimizing dopaminergics and non-pharmacologic interventions, are an essential part of the plan.

General Psychiatry
KEYWORDS dopamine geriatric-psychiatry neurology novel-medications nuplazid parkinsons
Randall Moore, MD, JD.

Is Ramelteon an Effective Hypnotic?

More from this author
Chris Aiken, MD.

The New Billing Codes

More from this author
www.thecarlatreport.com
Issue Date: March 30, 2020
SUBSCRIBE NOW
Table Of Contents
CME Post-Test - Psychopharmacology Algorithms, TCPR, April 2020
How to Choose an Antipsychotic in Schizophrenia
The Psychopharmacology Algorithm Project
Nuplazid: Novel Mechanism, Modest Benefits
Antipsychotics Fall Short in Delirium
Singulair and Suicide: FDA Strengthens Warning
DOWNLOAD NOW
Featured Book
  • MFB6eCover.jpg

    Medication Fact Book for Psychiatric Practice, Sixth Edition (2022)

    Guidance, clinical pearls, and bottom-line assessments covering the medications you use in your...
    READ MORE
Featured Video
  • therapist_canstockphoto9201097.jpg
    General Psychiatry

    Using SAMe In Clinical Practice with Garrett Rossi, MD

    Read More
Featured Podcast
  • canstockphoto4921771.jpg
    General Psychiatry

    Psychopharm Commandment #6: MAOIs

    MAOIs rank high in efficacy and are pretty well tolerated too, as long as you watch for two critical interactions.

    Listen now
Recommended
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png
  • Approaches to Autism Intervention

    January 31, 2022
    canstockphoto2240982_child-bubbles_thumb.jpg
  • Currently Available Cannabis Products

    September 1, 2022
  • Interpreting Assessment Discrepancies from Multiple Sources

    October 17, 2022
    ChildAssessment.png

About

  • About Us
  • CME Center
  • FAQ
  • Contact Us

Shop Online

  • Newsletters
  • Multimedia Subscriptions
  • Books
  • eBooks
  • ABPN Self-Assessment Courses

Newsletters

  • The Carlat Psychiatry Report
  • The Carlat Child Psychiatry Report
  • The Carlat Addiction Treatment Report
  • The Carlat Hospital Psychiatry Report
  • The Carlat Geriatric Psychiatry Report

Contact

info@thecarlatreport.com

866-348-9279

PO Box 626, Newburyport MA 01950

Follow Us

Please see our Terms and Conditions, Privacy Policy, Subscription Agreement, Use of Cookies, and Hardware/Software Requirements to view our website.

© 2023 Carlat Publishing, LLC and Affiliates, All Rights Reserved.